Research on small cell carcinoma, including small cell lung cancer

From November 2025

Ultrasensitive ctDNA detection improves prognostic stratification in NSCLC (ref: Black doi.org/10.1016/j.cell.2025.10.020/)
Local consolidative therapy enhances survival in NSCLC patients with oligo-residual disease (ref: Yang doi.org/10.1038/s41392-025-02460-z/)
MUC1-C is a potential target for overcoming TKI resistance in NSCLC (ref: Takamori doi.org/10.1038/s41392-025-02482-7/)
Andamertinib shows promising efficacy in EGFR exon 20 insertion-positive NSCLC (ref: Yang doi.org/10.1016/j.jtho.2025.11.008/)
The Lung Immune Prognostic Index may guide treatment in PD-L1-low/negative NSCLC (ref: Yoshimura doi.org/10.1016/j.esmoop.2025.105906/)
Dynamic monitoring of cfDNA methylation predicts response to neoadjuvant therapy in NSCLC (ref: Liu doi.org/10.1186/s12916-025-04419-x/)
Tislelizumab combined with anlotinib shows efficacy in extensive-stage SCLC (ref: Chen doi.org/10.1016/j.eclinm.2025.103502/)
PROTACs targeting CD26 represent a novel strategy for driver-negative NSCLC (ref: Zhang doi.org/10.1016/j.ebiom.2025.106026/)

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec